Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

The Economic Conundrum for Antibacterial Drugs.

Shlaes DM.

Antimicrob Agents Chemother. 2019 Dec 20;64(1). pii: e02057-19. doi: 10.1128/AAC.02057-19. Print 2019 Dec 20.

PMID:
31658969
2.

Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about it.

Shlaes DM, Bradford PA.

Pathog Immun. 2018 Feb 22;3(1):19-43. doi: 10.20411/pai.v3i1.231. eCollection 2018. Review. No abstract available.

3.

Research and Development of Antibiotics: The Next Battleground.

Shlaes DM.

ACS Infect Dis. 2015 Jun 12;1(6):232-3. doi: 10.1021/acsinfecdis.5b00048. Epub 2015 May 5.

PMID:
27622738
4.

Reply to "Simple solutions reflect misunderstanding of animal antibiotic use".

Metz M, Shlaes DM.

Antimicrob Agents Chemother. 2015 Jan;59(1):751. doi: 10.1128/AAC.04604-14. No abstract available.

5.

Eight more ways to deal with antibiotic resistance.

Metz M, Shlaes DM.

Antimicrob Agents Chemother. 2014 Aug;58(8):4253-6. doi: 10.1128/AAC.02623-14. Epub 2014 May 27.

6.

In memoriam: John P. Quinn, MD.

Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA.

Clin Infect Dis. 2014 Mar;58(5):748-50. doi: 10.1093/cid/cit801. Epub 2013 Dec 12. No abstract available.

7.

The FDA reboot of antibiotic development.

Shlaes DM, Sahm D, Opiela C, Spellberg B.

Antimicrob Agents Chemother. 2013 Oct;57(10):4605-7. doi: 10.1128/AAC.01277-13. Epub 2013 Jul 29. No abstract available.

8.

New β-lactam-β-lactamase inhibitor combinations in clinical development.

Shlaes DM.

Ann N Y Acad Sci. 2013 Jan;1277:105-14. doi: 10.1111/nyas.12010. Review.

PMID:
23346860
9.

Overcoming the challenges to developing new antibiotics.

Shlaes DM, Spellberg B.

Curr Opin Pharmacol. 2012 Oct;12(5):522-6. doi: 10.1016/j.coph.2012.06.010. Epub 2012 Jul 24. Review.

PMID:
22832234
10.

The pleuromutilin antibiotics: a new class for human use.

Novak R, Shlaes DM.

Curr Opin Investig Drugs. 2010 Feb;11(2):182-91. Review.

PMID:
20112168
11.

Telithromycin and the FDA: implications for the future.

Shlaes DM, Moellering RC.

Lancet Infect Dis. 2008 Feb;8(2):83-5. doi: 10.1016/S1473-3099(08)70002-1. No abstract available.

PMID:
18222155
12.

5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases.

Venkatesan AM, Agarwal A, Abe T, Ushirogochi H, Ado M, Tsuyoshi T, Dos Santos O, Li Z, Francisco G, Lin YI, Petersen PJ, Yang Y, Weiss WJ, Shlaes DM, Mansour TS.

Bioorg Med Chem. 2008 Feb 15;16(4):1890-902. Epub 2007 Nov 5.

PMID:
18061461
13.

Structure-activity relationship of 6-methylidene penems bearing 6,5 bicyclic heterocycles as broad-spectrum beta-lactamase inhibitors: evidence for 1,4-thiazepine intermediates with C7 R stereochemistry by computational methods.

Venkatesan AM, Agarwal A, Abe T, Ushirogochi H, Yamamura I, Ado M, Tsuyoshi T, Dos Santos O, Gu Y, Sum FW, Li Z, Francisco G, Lin YI, Petersen PJ, Yang Y, Kumagai T, Weiss WJ, Shlaes DM, Knox JR, Mansour TS.

J Med Chem. 2006 Jul 27;49(15):4623-37.

PMID:
16854068
14.

An update on tetracyclines.

Shlaes DM.

Curr Opin Investig Drugs. 2006 Feb;7(2):167-71. Review.

PMID:
16499287
15.

3,5-dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against gram-positive bacteria.

Yang Y, Severin A, Chopra R, Krishnamurthy G, Singh G, Hu W, Keeney D, Svenson K, Petersen PJ, Labthavikul P, Shlaes DM, Rasmussen BA, Failli AA, Shumsky JS, Kutterer KM, Gilbert A, Mansour TS.

Antimicrob Agents Chemother. 2006 Feb;50(2):556-64.

16.

Respiratory syncytial virus infection: an emerging or unappreciated infection?

Shlaes DM.

Semin Respir Crit Care Med. 2000;21(4):305-11.

PMID:
16088741
17.

Antibacterial drug discovery: is it all downhill from here?

Projan SJ, Shlaes DM.

Clin Microbiol Infect. 2004 Nov;10 Suppl 4:18-22. Review.

18.

Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.

Venkatesan AM, Agarwal A, Abe T, Ushirogochi H, Yamamura I, Kumagai T, Petersen PJ, Weiss WJ, Lenoy E, Yang Y, Shlaes DM, Ryan JL, Mansour TS.

Bioorg Med Chem. 2004 Nov 15;12(22):5807-17.

PMID:
15498657
19.

Hydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteria.

Dushin RG, Wang TZ, Sum PE, He H, Sutherland AG, Ashcroft JS, Graziani EI, Koehn FE, Bradford PA, Petersen PJ, Wheless KL, How D, Torres N, Lenoy EB, Weiss WJ, Lang SA, Projan SJ, Shlaes DM, Mansour TS.

J Med Chem. 2004 Jul 1;47(14):3487-90.

PMID:
15214775
20.

Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria.

Ruzin A, Singh G, Severin A, Yang Y, Dushin RG, Sutherland AG, Minnick A, Greenstein M, May MK, Shlaes DM, Bradford PA.

Antimicrob Agents Chemother. 2004 Mar;48(3):728-38.

21.

The abandonment of antibacterials: why and wherefore?

Shlaes DM.

Curr Opin Pharmacol. 2003 Oct;3(5):470-3. Review.

PMID:
14559090
22.

Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus.

Ruzin A, Severin A, Moghazeh SL, Etienne J, Bradford PA, Projan SJ, Shlaes DM.

Biochim Biophys Acta. 2003 May 2;1621(2):117-21.

PMID:
12726988
23.

Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction.

Ruzin A, Severin A, Ritacco F, Tabei K, Singh G, Bradford PA, Siegel MM, Projan SJ, Shlaes DM.

J Bacteriol. 2002 Apr;184(8):2141-7.

24.

The United States Food and Drug Administration and the end of antibiotics.

Shlaes DM, Moellering RC Jr.

Clin Infect Dis. 2002 Feb 1;34(3):420-2. No abstract available.

PMID:
11774094
25.

Role of Antimicrobial Stewardship in Prevention and Control of Antibiotic Resistance.

Shlaes DM.

Curr Infect Dis Rep. 1999 Oct;1(4):334-337.

PMID:
11095806
26.

Mechanism of inhibition of the class A beta -lactamases PC1 and TEM-1 by tazobactam. Observation of reaction products by electrospray ionization mass spectrometry.

Yang Y, Janota K, Tabei K, Huang N, Siegel MM, Lin YI, Rasmussen BA, Shlaes DM.

J Biol Chem. 2000 Sep 1;275(35):26674-82.

27.

Class A beta-lactamases--enzyme-inhibitor interactions and resistance.

Yang Y, Rasmussen BA, Shlaes DM.

Pharmacol Ther. 1999 Aug;83(2):141-51. Review.

PMID:
10511459
28.

Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.

Lin S, Thomas M, Shlaes DM, Rudin SD, Knox JR, Anderson V, Bonomo RA.

Biochem J. 1998 Jul 15;333 ( Pt 2):395-400.

29.

Adhesion of Staphylococcus epidermidis and transposon mutant strains to hydrophobic polyethylene.

Higashi JM, Wang IW, Shlaes DM, Anderson JM, Marchant RE.

J Biomed Mater Res. 1998 Mar 5;39(3):341-50.

PMID:
9468041
30.

Risk factors associated with permanent access-site infections in chronic hemodialysis patients.

Bonomo RA, Rice D, Whalen C, Linn D, Eckstein E, Shlaes DM.

Infect Control Hosp Epidemiol. 1997 Nov;18(11):757-61.

PMID:
9397369
31.

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals.

Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C.

Clin Infect Dis. 1997 Sep;25(3):584-99. Review.

PMID:
9314444
32.

Construction and characterization of an OHIO-1 beta-lactamase bearing Met69Ile and Gly238Ser mutations.

Bonomo RA, Knox JR, Rudin SD, Shlaes DM.

Antimicrob Agents Chemother. 1997 Sep;41(9):1940-3.

33.

OHIO-1 beta-lactamase mutants: Asp179Gly mutation confers resistance to ceftazidime.

Bonomo RA, Rudin SD, Shlaes DM.

FEMS Microbiol Lett. 1997 Jul 15;152(2):275-8.

34.

Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals.

Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C.

Infect Control Hosp Epidemiol. 1997 Apr;18(4):275-91.

PMID:
9131374
35.

Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.

Bonomo RA, Rudin SA, Shlaes DM.

FEMS Microbiol Lett. 1997 Mar 1;148(1):59-62.

36.

Peptidoglycan synthesis and structure in Staphylococcus haemolyticus expressing increasing levels of resistance to glycopeptide antibiotics.

Billot-Klein D, Gutmann L, Bryant D, Bell D, Van Heijenoort J, Grewal J, Shlaes DM.

J Bacteriol. 1996 Aug;178(15):4696-703.

37.

Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Rice LB, Eckstein EC, DeVente J, Shlaes DM.

Clin Infect Dis. 1996 Jul;23(1):118-24.

PMID:
8816140
38.

Serogroup-specific epidemiology of Streptococcus pneumoniae: associations with age, sex, and geography in 7,000 episodes of invasive disease.

Scott JA, Hall AJ, Dagan R, Dixon JM, Eykyn SJ, Fenoll A, Hortal M, Jetté LP, Jorgensen JH, Lamothe F, Latorre C, Macfarlane JT, Shlaes DM, Smart LE, Taunay A.

Clin Infect Dis. 1996 Jun;22(6):973-81.

PMID:
8783696
40.

Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus.

Mainardi JL, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW.

J Infect Dis. 1995 Jun;171(6):1646-50.

PMID:
7769310
41.

Vancomycin resistance in the enterococcus. Relevance in pediatrics.

Rice LB, Shlaes DM.

Pediatr Clin North Am. 1995 Jun;42(3):601-18. Review.

PMID:
7761143
42.

Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin.

Shlaes DM, Shlaes JH.

Clin Infect Dis. 1995 Apr;20(4):1071-3. No abstract available.

PMID:
7795059
43.

Bacteremia due to vancomycin-dependent Enterococcus faecium.

Green M, Shlaes JH, Barbadora K, Shlaes DM.

Clin Infect Dis. 1995 Mar;20(3):712-4.

PMID:
7756503
44.

beta-Lactamase mutations far from the active site influence inhibitor binding.

Bonomo RA, Dawes CG, Knox JR, Shlaes DM.

Biochim Biophys Acta. 1995 Feb 22;1247(1):121-5.

PMID:
7873581
45.

Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase.

Bonomo RA, Dawes CG, Knox JR, Shlaes DM.

Biochim Biophys Acta. 1995 Feb 22;1247(1):113-20.

PMID:
7873579
46.

Glycopeptide resistance in gram-positive pathogens.

Fraimow HS, Shlaes DM.

Adv Exp Med Biol. 1995;390:81-95. Review. No abstract available.

PMID:
8718604
47.
48.
49.

Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.

Shlaes DM, Baughman R, Boylen CT, Chan JC, Charan NB, Cormier YC, Erickson A, Grossman R, Kirmani N, Suh B, et al.

J Antimicrob Chemother. 1994 Oct;34(4):565-77.

PMID:
7868408
50.

Bacterial resistance to the cyclic glycopeptides.

Shlaes DM, Rice LB.

Trends Microbiol. 1994 Oct;2(10):385-8.

PMID:
7850206

Supplemental Content

Loading ...
Support Center